Kevin Kunzmann

Positive findings for the envelope support some of the first indications that a preventive measure could address cardiac surgery infection rates.

The novel Person-Centered Primary Care Measure has established 11 domains that each represent a single item representing the broad scope of primary care. The team behind it has created a measure that “actually aligns with the work of primary care physicians, and what matters to patients.”

Dalteparin sodium injection was shown to result in VTE resolution in a majority of treated patients from a clinical trial.

Patients on 2 different doses of the once-daily oral JAK1 inhibitor reached statistically significant measures for improved symptoms.

Patients diagnosed with psoriasis face a nearly three-fold greater risk of developing anxiety disorders.

Assaults have become common in emergency departments. Organizers and individuals are calling on caregivers and administrators to collaborate on real solutions.

A new test involving pediatric lung function shows that just 15% of patients will achieve strict remission in adulthood.

The investigative drug SEP-363856 has been evidenced in a phase 2 trial to reduced hospitalized patient symptoms and severity.

Findings from ASCENT-COPD show the long-acting muscarinic antagonist is noninferior to placebo in driving major adverse cardiovascular event risk in very at-risk patients with COPD.

New data from PARTNER 3 shows the procedure reduces one-year mortality in patients with aortic stenosis.

Telehealth and technology have broadened the capabilities of surgeons.

Tafamidis and tafamidis meglumine reported a greater survival rate in treated patients than those administered placebo, and reported a reduced rate of hospitalizations from cardiovascular problems.

Esketamine nasal spray is currently relegated to a specific depression patient population, but that may not be for long.

The SmartSync includes a mobile application, telemetry head, and pacing system analyzer that allows for direct patient-to-physician data sharing.

The GSK triple-combination FF/UMEC/VI inhaler reported significant lung function improvement in patients with inadequately controlled asthma.

The tropical-based virus is prevalent in areas inhabited by about one-third of the world's population.

The lot is being voluntarily recalled due to a detected microbial growth during a routine manufacturing simulation—indicating a potential introduction of microorganisms into the therapy.

How wearable devices and their massive patient pools have created a balancing act between mass patient arrhythmia data collection and individualized care.

In a 47-patient study, all who received the therapy for either 8 or 16 weeks had no detected virus in their blood samples post-12 weeks, indicating cured infection.

Recent findings show that borderline deficiency is prevalent in about half of all stroke patients. Are vitamin B1 levels being tested enough, and are deficiencies affecting stroke rehabilitation?

How does a cardiologist balance the benefits of invasive care with the patients' interest in non-invasive measures?

Data from ACC 2018 showed the PCSK9 inhibitor is associated with an absolute risk reduction of 1.6% in treated patients versus placebo.

The device could help lessen the great rate of donor lungs not suitable for transplant.

The selective serotonin inverse agonist, previously approved for Parkinson symptoms, could soon seek FDA approval as an adjunctive therapy.

New COMMANDER HF post hoc data shows more evidence the blood-thinning therapy has some effect on potentially deadly cardiovascular events.

The FDA approved the Monarch electronic Trigeminal Nerve Stimulation based on the findings of a trial involving children aged 7-12 years old.

A new study of 55 million insured young adults in the US found that major depression, type 2 diabetes, and other conditions are becoming more prevalent among them.

The LOTUS Edge Aortic Valve System was approved in Europe just 1 month ago, and will be available in the US the following weeks.

The Apple Watch-friendly platform is the first cleared by the FDA to detect and report the 3 common arrhythmias, including atrial fibrillation.

A retroactive review of patients referred to a psychiatric consultant found that most patients left with a different diagnosis.